ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage

This study has been terminated.

Sponsored by: University of Michigan Cancer Center
Information provided by: University of Michigan Cancer Center
ClinicalTrials.gov Identifier: NCT00156260
  Purpose

The primary purpose of this research is to analyze the cells present in the fluid obtained via ductal lavage from the nipple of a woman with a known diagnosis of breast cancer. A portion of the lavage fluid may be used in future breast cancer biomarkers. Remaining lavage fluid will be used to analyze its biochemical composition, for investigational purposes only.


Condition Intervention
Breast Cancer
Procedure: Ductal lavage

Genetics Home Reference related topics:   breast cancer   

MedlinePlus related topics:   Breast Cancer    Cancer   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Prospective
Official Title:   UMCC 2-48 Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage

Further study details as provided by University of Michigan Cancer Center:

Estimated Enrollment:   88
Study Start Date:   January 2003
Study Completion Date:   October 2008
Primary Completion Date:   October 2008 (Final data collection date for primary outcome measure)

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  1. 18 years of age
  2. biopsy-proven unilateral invasive breast cancer of any histology or ductal carcinoma in situ
  3. patient desires or requires treatment with mastectomy
  4. any patient who has undergone prior excisional biopsy of their primary breast tumor must have had margins positive for disease, or must have either mammographic or ultrasonographic evidence of probable residual disease in the breast.
  5. patients receiving induction chemotherapy remain eligible for participation in the study regardless of tumor response; those with a clinical complete response remain eligible.
  6. voluntarily signed informed consent. -

Exclusion Criteria:

  1. male gender
  2. lobular carcinoma in situ as the only cancerous histology
  3. prior margin-negative excisional biopsy of primary breast tumor, with no evidence of residual disease
  4. patient being treated with breast conservation therapy inability to understand the nature of the procedure pregnancy and/or active lactation
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156260

Locations
United States, Michigan
University of Michigan Cancer Center    
      Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators
University of Michigan Cancer Center

Investigators
Principal Investigator:     Lisa Newman, M.D.     University of Michigan Cancer Center    
  More Information


Study ID Numbers:   UMCC 2-48
First Received:   September 8, 2005
Last Updated:   October 4, 2008
ClinicalTrials.gov Identifier:   NCT00156260
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers